학술논문
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure.
Document Type
Article
Author
Source
Subject
*NON-alcoholic fatty liver disease
*ASPARTATE aminotransferase
*FATTY liver
*BARIATRIC surgery
*INSULIN resistance
*HEPATIC fibrosis
*
*
*
*
*
Language
ISSN
0013-726X
Abstract
Finally, given that most improvements in NAFLD were correlated with amelioration in obesity-related outcomes, it is unclear whether POSE 2.0 would be helpful for nonobese NAFLD patients. Measures of obesity, insulin resistance, and patient-reported outcomes In the POSE 2.0 arm, mean BMI improved from 37.9 kg/m SP 2 sp (95 %CI 36.7 to 39.1) at baseline to 31.6 kg/m SP 2 sp (95 %CI 29.1 to 33.5) at 12 months ( I P i < 0.001) ( B Table 3 s b ). Graph Introduction Nonalcoholic fatty liver disease (NAFLD) continues to rise as a common cause of chronic liver disease globally [1]. All patients experienced stable or improved fibrosis stages in both arms at 6 and 12 months, except for one patient in the POSE 2.0 arm who experienced worsening of fibrosis from 4.8 kPa (F0-F1) to 8.3 kPa (F3) at 12 months (Table 1). [Extracted from the article]